secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2021-08-16T23:59:59+00:00
Accession:  0001193125-21-246896
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q2 net loss $16.5M; cash $218.1M; initiates Phase 2 APEX trial for bezuclastinib in AdvSM
--------------------------------------------------------------------------------

- Net loss of $16.5M for Q2 2021 vs $7.4M in Q2 2020; R&D spend $12.4M, G&A $4.9M.
- Cash and equivalents $218.1M as of June 30, 2021; expects runway into 2024.
- Phase 2 APEX open-label study of bezuclastinib in Advanced Systemic Mastocytosis initiated; preliminary data expected 1H 2022.
- SUMMIT Phase 2 study in NonAdvSM on track to start 2H 2021 after positive FDA interactions.
- FDA granted orphan drug designation for bezuclastinib in GIST; new study with sunitinib planned 2H 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312521246896/0001193125-21-246896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312521246896/d204129d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-246896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer